in vitro News and Research

RSS

Sanofi Pasteur signs agreement to acquire VaxDesign

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.

28 Sep 2010

Researchers identify cellular/molecular defect in T cell regulatory pathway

Researchers at Columbia University Medical Center have identified a defect in the T cell regulatory pathway which normally controls autoreactive T cells that attack the body's own tissues and organs. A majority of people with Type 1 diabetes who were tested in the study were found to have the newly-identified cellular/molecular defect, and the researchers were able to successfully correct the defect in-vitro.

27 Sep 2010

Bio-Dome wound interface dressings superior than GranuFoam

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results. The Engenex Negative Pressure Wound Therapy (NPWT) system's Bio-Dome wound interface showed superior tensile strength and lower simulated bioadhesion when compared with GranuFoam (polyurethane foam).

27 Sep 2010

Calcitonin combination therapy may help treat osteoarthritis: Study

Tarsa Therapeutics, Inc. and Unigene Laboratories, Inc. today reported preclinical data showing that calcitonin may have synergistic effects in combination with other drugs in reducing the collagen degradation associated with osteoarthritis.

27 Sep 2010

Tolerx presents otelixizumab preclinical research at 46th EASD

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.

23 Sep 2010

Children conceived by IVF score better than age- and gender-matched peers: Study

Children conceived by in vitro fertilization (IVF) perform at least as well as their peers on academic tests at all ages from grade 3 to 12, according to a new University of Iowa study.

23 Sep 2010

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that the National Cancer Institute has purchased Caliper's Quantum FX, a stand-alone microCT system for pre-clinical imaging, to study spontaneous tumor models in lung cancer.

23 Sep 2010

MDI and Integrated Sciences enter exclusive distribution agreement for Detect-Ready MRSA assay in Australia

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Integrated Sciences Pty. Ltd. today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready MRSA assay in Australia.

22 Sep 2010

Scientists develop new therapy for treatment of skin, lung cancer

Scientists at the University of Granada have developed a new therapy for the treatment of skin and lung cancer. This therapy involves the use of a suicide coliphage-gene (gene E) that can induce death to cells transfected with it.. Their studies have demostrated that this technique is not only effective in vitro (using tumour cell cultures), but also in vivo through the use of experimental animals in which tumours were induced.

22 Sep 2010

PRC offers 'IVF Second Chances' program to fertility patients

Fertility patients who don't get pregnant on their first try at in vitro fertilization (IVF) will get a second chance for free at Pacific Reproductive Center (PRC), under a new program the fertility clinic announced today.

22 Sep 2010

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

Researchers identify protein essential for dendritic cell development

A protein called PU.1 is essential for the development of dendritic cells, the sentinels of the immune system, Walter and Eliza Hall Institute researchers in Melbourne, Australia, have shown.

20 Sep 2010

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.

20 Sep 2010

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Athersys, Inc. announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University.

20 Sep 2010

Asthma symptoms peak 17 days after Labor Day: Study

Next week, Thursday could be the worst day of the year for people with asthma. If past experience holds, on September 23 there will be 3 times more asthma-related deaths and 4 times more asthma-related hospitalizations than on any other day of the year.

18 Sep 2010

Researchers reveal Prozac reactions to increase serotonin level

The response time to antidepressants, such as Prozac, is around three weeks. The adaptation mechanisms of the neurons to antidepressants has, until now, remained enigmatic. In particular, the researchers have revealed, for the first time, a sequence of reactions caused by Prozac at the neuron level, which contributes to an increase in the amounts of serotonin, a chemical "messenger" essential to the brain, and deficient in depressive individuals.

17 Sep 2010

Fred Hutchinson Cancer Center research team wins 2010 BioFlux Innovation Award

Fluxion Biosciences, Inc. announced today that a research team from Fred Hutchinson Cancer Center has won the 2010 BioFlux Innovation Award competition. Laura Sycuro, Ph.D., a post-doctoral research fellow in the lab of David Fredricks, M.D., authored the winning submission which focuses on screening and characterizing bacterial strains involved in biofilm-related infections known to affect women's reproductive health.

From Fluxion Biosciences 17 Sep 2010

IVF on the rise in Australia: Report

According to a Federal Government report there are now more births via In Vitro Fertilization (IVF) treatment than ever before in Australia. There has been a 45% rise in the number of babies born through IVF and other treatments between 2004-08, according to the Australian Institute of Health and Welfare report released today. In 2008 there were 10,509 babies born through fertility treatments in Australia.

16 Sep 2010

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic resistant infections, delivered four poster presentations on its Aganocide compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA.

16 Sep 2010

NMS Labs launches method for K2 drug metabolites detection in urine

Of growing concern to public health officials and law enforcement is that routine drug testing cannot detect the use of the popular and highly intoxicating new drugs K2 and Spice. NMS Labs now has a full menu of tests that can detect the use of the designer chemicals present in these products, sold as incense or legal highs. A few weeks ago, NMS Labs launched a blood test to detect a range of these laboratory-designed synthetic drugs.

16 Sep 2010